We report a novel marine polysaccharide-based biomimetic bilayer scaffold, d-ACT@MIC/SIM, featuring a dense upper layer serving as a barrier layer and a porous lower layer mimicking the native bone matrix microenvironment. This sophisticated architecture, coupled with the programmed co-delivery of minocycline and simvastatin, endowed the scaffold with a multifaceted therapeutic armamentarium. In vitro assessments identified its significant antibacterial efficacy and osteoinductive potential. Animal experiments further validated its capacity to suppress inflammatory cytokine expression and facilitate alveolar bone regeneration. The integrated strategy of a structurally biomimetic, dual drug-releasing scaffold thus offers a significant advancement over conventional therapeutic modalities for periodontitis by concurrently addressing infection, inflammation, and tissue regeneration. As such, this innovative bilayer asymmetric bionic drug-carrying scaffolds emerge as a compelling and prospective therapeutic option for advancing periodontitis treatment.

research team from KAIST, Chonnam National University, KRIBB, and KBSI develops a prodrug that works in the Alzheimer’s disease brain

peroxide, a dementia-associated causative substance, is used as a therapeutic signal, reducing side effects and enhancing dementia treatment efficacy